AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05126199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks.~Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12).
Study NCT05126199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal ad libitum diet
Description: Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed.~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12).
Study NCT06646900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted CBT (CaCBT) based guided self-help manual
Description: The intervention consists of seven modules including cognitive restructuring, problem solving, behavioural activation and conflict management. Three additional modules focus on interpersonal relationships, mental health wellbeing and self-care. Each module is delivered over one week. The intervention uses culturally appropriate stories, drawings, examples from local folklore and religious context to describe the concepts of CBT.
Study NCT06646900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard CBT Manual
Description: The standard CBT manual will follow conventional CBT techniques without specific cultural adaptations
Study NCT06107205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TTYP01
Description: 1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)
Study NCT06107205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radicava
Description: 1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
Study NCT06107205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radicava ORS
Description: 1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
Study NCT06148337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: unhydrolyzed eggshell membrane
Description: an unhydrolyzed, minimally processed chicken eggshell membrane powder.
Study NCT06148337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: psyllium husk fiber powder
Study NCT06127979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core needle biopsy
Description: Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied
Study NCT06127979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Description: blood draw
Study NCT05110625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preDIABE-TEXT
Description: Participants will receive text messages (three per week) in their mobile phones during six months.
Study NCT05110625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Education
Description: Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
Study NCT04448184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously.
Study NCT04326569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample to quantify copeptin
Study NCT06346756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of dental caries.
Description: The researchers used G-aenial Universal Injectable (GCI), G-aenial A'CHORD (GCA), Tetric Prime (TP), and Filtek Ultimate (FU) composites for premolar Class II restorations.
Study NCT06476743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensory Integration Therapy
Description: This group will receive sensory integration therapy for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week for 8 week.
Study NCT06476743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Board Training
Description: This group will receive balance board training for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week.
Study NCT04406129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT capsules
Description: Intervention: FMT capsules containing extensively screened donor stool.
Study NCT04406129 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Intervention: Placebo capsules that do not contain donor stool or any active drug.
Study NCT05883852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
Study NCT05883852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
Study NCT05883852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
Study NCT05883852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,
Study NCT05883852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,
Study NCT05883852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).
Study NCT05883852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).
Study NCT05883852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
Study NCT05883852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
Study NCT05303987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Description: After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given.
Study NCT05303987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Description: After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given.
Study NCT04955626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular Injection
Study NCT04955626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injection
Study NCT04955626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 OMI
Description: Intramuscular Injection
Study NCT04955626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination BNT162b2 and BNT162b2 OMI
Description: 30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection
Study NCT04955626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination (Bivalent) BNT162b2 and BNT162b2 OMI
Description: 30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection
Study NCT06497257 — intervention group
Intervention type: OTHER
Intervention: Evaluating wrist flexor and extensor peak torque
Description: Evaluation of wrist flexor and extensor peak torque
Study NCT06497257 — intervention group
Intervention type: OTHER
Intervention: Evaluating functional disability
Description: Evaluation of functional disability
Study NCT06497257 — intervention group
Intervention type: OTHER
Intervention: Evaluating hand grip strength
Description: Evaluation of hand grip strength
Study NCT05066100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal Use of Supple Cups
Description: For pregnant women identified with FIRN and providing consent to participate in this study, Supple Cup usage will be initiated at 32 weeks gestation to begin to elongate the nipples in preparation for breastfeeding.
Study NCT06200688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEANUT BALL
Description: Experimental Group: Pregnant women who were applied with a peanut ball were informed about the necessary information related to the ball by the midwife with a visual representation of the positions. A total of 5 positions were shown to the pregnant women. Peanut ball was started to be used when the cervical dilation reached 6 cm. Pregnant women in the active phase, the transition phase, and the second stage of labor where the peanut ball was applied were directed to change positions every 30-45 minutes. Importance was given to selecting positions where the pregnant woman felt comfortable.~Control Group: No intervention was made other than routine practices within the clinic for pregnant women. It was generally observed that pregnant women spent the time until delivery lying down and connected to electronic fetal monitoring.
Study NCT05395624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-OP-801
Description: 18F Hydroxyl Dendrimer
Study NCT06189040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2 30µg
Description: intramuscular administration of 30µg
Study NCT06189040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 30µg
Description: intramuscular administration of 30µg
Study NCT06189040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2 20µg
Description: intramuscular administration of 20µg
Study NCT06189040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT162b2 6µg
Description: intradermal administration of 6µg
Study NCT06189040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-1273 100µg
Description: intramuscular administration of 100µg
Study NCT06189040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273 100µg
Description: intramuscular administration of 100µg
Study NCT06189040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-1273 50µg
Description: intramuscular administration of 50µg
Study NCT06189040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChAdOx1-S [Recombinant]
Description: intramuscular administration of not less than 2.5 x 10\^8 infectious units
Study NCT06381908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-restriction with low carbohydrate
Description: Calorie-restriction and low carbohydrate availability
Study NCT06381908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie-restriction with moderate carbohydrate
Description: Calorie-restriction and moderate carbohydrate availability
Study NCT05104658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-targeted rehabilitation offers
Description: In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
Study NCT05093452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a midwife. The midwife will have first received a standardized 3 days training session on the content and techniques of MI. The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.
Study NCT05093452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information flyer
Description: Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the midwife.
Study NCT06573905 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention. this is observational study.
Study NCT05267301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AlmegaPL (FDA NDIN # 826)
Description: The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA). EPA is a type of omega-3 essential fatty acid known to play a beneficial role in protection against cardiovascular disease. Iwi/Cholesterol is the only source of long chain omega-3 that does not contain the DHA that is present in other omega-3 sources (fish oil, krill oil, other algal oils). Almega®PL was registered at the Food and Drug Administration (FDA) as a New Dietary Ingredient (NDIN) in 2014.
Study NCT05341089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study NCT05917093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored HLWD
Description: Participants receive the culturally tailored HLWD intervention for 6 weeks~* Week 0 - Baseline enrollment.~* Weeks 1-6 will consist of 6 separate group sessions. Diabetes self-management topics will be covered by 2 Black HLWD Facilitators. Participants will meet once a week, for a 2½-hour session, in community settings such as a community center, or church.
Study NCT04934891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION547
Description: ION547 will be administered by SC injection.
Study NCT04934891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ION547-matching placebo will be administered by SC injection.
Study NCT05652894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: Drug: HX008 200 mg ,Q3W
Study NCT05652894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice Chemotherapy
Description: Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin~Drug: cetuximab 400 mg/sqm initial dose, then 250 mg/sqm once weekly thereafter. Other Name: Erbitux~Drug: oxaliplatin 8 5 mg/sqm by IV, day1. Component of mFOLFOX6.~Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI.~Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI.~Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46\~48 h.Component of mFOLFOX6 or FOLFORI.
Study NCT05884333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Chemotherapy
Description: Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 \& -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours \& Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).
Study NCT05884333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood graft
Description: The double-unit CB graft will be infused on day 0 per standard practice.
Study NCT06044740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration of 0.4% (corresponding to 0.2 Minimum Alveolar Concentration) is reached.
Study NCT06044740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
Study NCT05605184 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey
Study NCT05330143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22 1mg/kg
Description: ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.
Study NCT05330143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22 2.5mg/kg
Description: ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.
Study NCT05330143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy
Description: standard antiretroviral therapy including Integrase inhibitors (INSTIs)
Study NCT05330143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiretroviral Therapy
Description: standard antiretroviral therapy including Integrase inhibitors (INSTIs)
Study NCT05330143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline vials administered subcutaneously once 4 week.
Study NCT04129515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A
Description: •NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle
Study NCT04129515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle
Study NCT06072755 — intervention group
Intervention type: DEVICE
Intervention: Finger pulse oximetry probe
Description: This finger probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
Study NCT06072755 — intervention group
Intervention type: DEVICE
Intervention: Transreflectance oximetry probe
Description: This neck probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
Study NCT05366153 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT
Description: Screening/Management Plan
Study NCT05742061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
Study NCT05742061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: PRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.